Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan.

Togashi T, Yamaji M, Thompson A, Giardina PC, Aizawa M, Patterson S, Gruber WC, Scott DA; 3003 Study Group..

Pediatr Infect Dis J. 2013 Sep;32(9):984-9. doi: 10.1097/INF.0b013e318293007e.

PMID:
23538524
2.

Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: a meta-analysis.

Ruiz-Aragón J, Márquez Peláez S, Molina-Linde JM, Grande-Tejada AM.

Vaccine. 2013 Nov 4;31(46):5349-58. doi: 10.1016/j.vaccine.2013.09.008. Review.

PMID:
24055349
3.

Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity.

Deloria Knoll M, Park DE, Johnson TS, Chandir S, Nonyane BA, Conklin L, Fleming-Dutra KE, Loo JD, Goldblatt D, Whitney CG, O'Brien KL.

Pediatr Infect Dis J. 2014 Jan;33 Suppl 2:S119-29. doi: 10.1097/INF.0000000000000079. Review.

4.

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13®].

Duggan ST.

Drugs. 2010 Oct 22;70(15):1973-86. doi: 10.2165/11205110-000000000-00000. Review.

PMID:
20883054
5.

13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents.

Plosker GL.

Paediatr Drugs. 2013 Oct;15(5):403-23. doi: 10.1007/s40272-013-0047-z. Review.

PMID:
24030738
6.

Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children.

Paradiso PR.

Clin Infect Dis. 2011 May;52(10):1241-7. doi: 10.1093/cid/cir142. Review.

7.

Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy.

Madhi SA, Cohen C, von Gottberg A.

Vaccine. 2012 Sep 7;30 Suppl 3:C21-7. doi: 10.1016/j.vaccine.2012.05.055. Review.

PMID:
22939016
8.

Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV).

Croxtall JD, Keating GM.

Paediatr Drugs. 2009;11(5):349-57. doi: 10.2165/11202760-000000000-00000. Review.

PMID:
19725600
9.

Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006).

Oosterhuis-Kafeja F, Beutels P, Van Damme P.

Vaccine. 2007 Mar 8;25(12):2194-212. Review.

PMID:
17267077
10.

Review on the immunogenicity and safety of PCV-13 in infants and toddlers.

Nunes MC, Madhi SA.

Expert Rev Vaccines. 2011 Jul;10(7):951-80. doi: 10.1586/erv.11.76. Review.

PMID:
21806394
11.

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): in older adults.

Sanford M.

Drugs. 2012 Jun 18;72(9):1243-55. doi: 10.2165/11209330-000000000-00000. Review.

PMID:
22686616
12.

Prevnar 13, the new 13-valent pneumococcal conjugate vaccine.

Sucher AJ, Chahine EB, Nelson M, Sucher BJ.

Ann Pharmacother. 2011 Dec;45(12):1516-24. doi: 10.1345/aph.1Q347. Review.

PMID:
22045904
13.

Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals.

Nunes MC, Madhi SA.

Hum Vaccin Immunother. 2012 Feb;8(2):161-73. doi: 10.4161/hv.18432. Review.

14.

The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity.

Park DE, Johnson TS, Nonyane BA, Chandir S, Conklin L, Fleming-Dutra KE, Loo JD, Goldblatt D, Whitney CG, O'Brien KL, Deloria Knoll M.

Pediatr Infect Dis J. 2014 Jan;33 Suppl 2:S130-9. doi: 10.1097/INF.0000000000000081. Review.

15.

Pneumococcal vaccination of older adults: conjugate or polysaccharide?

Fedson DS, Guppy MJ.

Hum Vaccin Immunother. 2013 Jun;9(6):1382-4. doi: 10.4161/hv.24692. Review.

16.

PCVs in individuals at increased risk of pneumococcal disease: a literature review.

Fletcher MA, Balmer P, Bonnet E, Dartois N.

Expert Rev Vaccines. 2015 Jul;14(7):975-1030. doi: 10.1586/14760584.2015.1037743. Review.

PMID:
26083459
17.

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): a guide to its use in older adults.

Scott LJ, Sanford M.

Drugs Aging. 2012 Oct;29(10):847-55. doi: 10.1007/s40266-012-0017-0. Review.

PMID:
23038610
18.

Recent approaches in vaccine development against Streptococcus pneumoniae.

Tarahomjoo S.

J Mol Microbiol Biotechnol. 2014;24(4):215-27. doi: 10.1159/000365052. Review.

19.

Pneumococcal immunization in immunocompromised hosts: where do we stand?

Cordonnier C, Averbuch D, Maury S, Engelhard D.

Expert Rev Vaccines. 2014 Jan;13(1):59-74. doi: 10.1586/14760584.2014.859990. Review.

PMID:
24308578
20.
Items per page

Supplemental Content

Support Center